This study aimed to investigate the epidemiology of hepatitis C virus (HCV) genotypes in the Middle East and North Africa (MENA) through an analytical and quantitative meta-regression methodology. For the most common genotypes 1, 3, and 4, country/subregion explained more than 77% of the variation in the distribution of each genotype. Genotype 1 was common across MENA, and was more present in high-risk clinical populations than in the general population. Genotype 3 was much more present in Afghanistan, Iran, and Pakistan than the rest of countries, and was associated with transmission through injecting drug use. Genotype 4 was broadly disseminated in Egypt in all populations, with overall limited presence elsewhere.
time, an analytical and quantitative approach to investigate the epidemiology of HCV genotypes, through meta-regressions, as applied to HCV genotype distribution in MENA. This study is part of the MENA HCV Epidemiology Synthesis Project, an ongoing endeavor to delineate HCV epidemiology and inform key public health research, policy, and programming priorities in MENA. 7, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] 2 | METHODS Studies reporting HCV genotype data were retrieved from the MENA HCV Epidemiology Synthesis Project database, 2 originally for an earlier study of HCV genotypes in MENA. 7 This comprehensive database consists of several subdatabases on different HCV epidemiological measures, and was populated through a series of systematic reviews for HCV infection across MENA. [10] [11] [12] [13] [14] [15] [16] [17] 26 The reviews followed the same methodology, informed by the Cochrane Collaboration handbook, 27 and used the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines 28 to report their findings.
In these reviews, genotype information were extracted from individual studies to populate the HCV genotype subdatabase.
Participants with untypeable genotype were removed from the sample size of the study. Participants with mixed genotypes contributed separately to the quantification of each genotype. The population of each study was classified into six risk categories based on the exposure risk to HCV infection, as presented in Figure 1 and as informed by existing literature [29] [30] [31] and our earlier studies. [10] [11] [12] [13] [14] [15] [16] [17] 26 A total of 175 genotype studies on 15 960 participants were included.
Univariable and multivariable random effects meta-regressions were conducted for the proportion of each HCV genotype, based on established statistical methodology, 27 to assess the association between genotype and each of country/subregion and population classification. Variables with a likelihood ratio test P < .2 in the univariable analysis qualified for inclusion in the multivariable analysis.
Relative risks and adjusted relative risks (ARRs) with a P value between .05 and .10 in the multivariable model, for any association between genotype and a given factor, indicated good evidence for the association. P ≤ .05 indicated strong evidence for the association.
| RESULTS
The results of the meta-regressions are shown in Table 1 with key results described in the following subsections.
| Genotype 1
There was strong evidence for variation in genotype 1 distribution by country/subregion, and good evidence for variation by population.
Relative to Egypt, all countries/subregions had much higher presence of genotype 1, apart from Pakistan. Genotype 1 was also more present in high-risk clinical populations (ARR of 1.2 [95% confidence interval [CI]:1.0-1.5]) than in the general population. Country/subregion and population explained the vast majority of the variation in genotype 1 distribution (84.4%), mostly through the country/subregion variable.
| Genotype 2
There was strong evidence for variation in genotype 2 distribution by country/subregion and by population. Relative to Egypt, the Gulf, 
| Genotype 3
There was strong evidence for variation in genotype 3 distribution by country/subregion, and good evidence for variation by population.
Relative to Egypt, all countries/subregions had substantially higher presence of genotype 3. This was particularly so for Afghanistan, Iran, and Pakistan, that had much higher presence of this genotype.
Genotype 3 was also more present in PWID (ARR of 1.7 [95% CI: 1.0-3.0]) than in the general population. Country/subregion and population explained the vast majority of the variation in genotype 3 distribution (77.9%), mostly through the country/subregion variable.
A sensitivity analysis (Table S1 ) was performed in which the meta-regressions were performed excluding countries in which genotype 3 was the most dominant genotype (Afghanistan and Pakistan but not Iran 7 ). The analysis was conducted to assess the purported global association between this genotype and PWID. 6 It The adjusted R-squared for the full model. was found that there is indeed strong evidence for an association between this genotype and PWID (ARR of 2.7 [95% CI: 1.2-5.8]).
The sensitivity analysis also confirmed the strong evidence for variation by country/subregion-country/subregion and population explained the majority of the variation (66.4%), mostly through the country/subregion variable.
| Genotype 4
There was strong evidence for variation in genotype 4 distribution by country/subregion, with most countries having substantially lower 
| Genotype 5
Unlike the other genotypes, most of the variation in the distribution of genotype 5 was explained by the population variable, rather than the country/subregion variable. Paradoxically also, compared with the general population, there was strong evidence for higher presence of this genotype in special clinical populations, but lower presence in high-risk clinical populations. Moreover, of all countries/ subregions, only the Fertile Crescent had higher presence of genotype 5 relative to Egypt. Population and country/subregion explained 57.3% of the variation in genotype 5 distribution. These results, which are epidemiologically not easy to interpret, could be an artifact of the very low presence of this genotype in the MENA region. 7 Genotype 5 was identified in only 3.9% of all genotype studies, with only 0.1% of infections being with this genotype.
| Genotype 6 and genotype 7
There were too few studies in which genotype 6 was identified (1.7%), resulting in very broad confidence intervals of limited implications, thus no analyses are reported for this genotype. No study identified the presence of genotype 7 in MENA.
| DISCUSSION
We used a quantitative analytical approach to investigate epidemiological associations for HCV genotypes, with application to the MENA region. The utility of this approach was demonstrated-the study yielded estimates for the differences in genotype distributions by country/subregion and by population type. Overall, country/ subregion explained most of the variation, highlighting geography as the principal determinant of genotype distribution. Interestingly, we found evidence for an association between genotype 1 and high-risk clinical populations, possibly explaining, with the global presence of these populations, the common presence of this genotype across countries. 6 This finding also supports existing literature suggesting such an association. 6 We further found an association between genotype 3 and PWID, thereby supporting an apparently global role for this genotype in HCV transmission through injecting drug use. 6 While these findings were generated for MENA, they may reflect generic results of global relevance.
Genotype epidemiology in the region may have been influenced by several factors. The importation of contaminated blood products, before the onset of blood screening, primarily from Western countries, has been linked to a fraction of reported HIV cases, 32, 33 and presumably helped disseminate HCV genotype 1 across the region. 6 Genotype 1 was ubiquitous across most countries and subregions of MENA, which may also be attributed to population movement links to countries outside of MENA, as genotype 1 is the most common genotype globally. 6, 30 For example, the presence of genotype 1 was highest in the Maghreb subregion, almost 11-fold higher than in Egypt, a subregion which has strong migration links with western and southern Europe. 34, 35 The emerging HIV epidemics among PWID in MENA, and specifically in Afghanistan, Iran, and Pakistan, have been linked to overlapping injecting networks across these countries. [36] [37] [38] This may have (partially) contributed to the relatively larger presence of genotype 3 among PWID in these countries. A strong presence of genotype 4 was found in Egypt. Phylogenetic evidence has shown that genotype 4 in this country originated from central Africa, 39 and circulated endemically until the mass expansion of the HCV epidemic through the parenteral antischistosomal therapy (PAT) campaigns and other healthcare practices. 10, 11, [39] [40] [41] [42] [43] Genotype 4 was also found to be present in countries that host large migrant labor populations from Egypt, 44 such as in countries of the Fertile Crescent 13 and Gulf 26 subregions of MENA. 7, 18 This study had limitations. HCV genotype data were not available for several countries. The number of studies also varied by population type and country/subregion, and the sample size of genotyped individuals was small for a number of studies-we may not have had sufficient statistical power to discern specific associations.
This may explain the lack of a clear interpretation/identification of epidemiological associations for genotype 5. We assessed associations for specific key factors that were available in extracted data, but we were unable to assess the role of a broader set of factors. This may clarify why most variation in genotype 2 distribution remained unexplained. Despite these limitations, we were able to utilize a breadth of genotype data that was systematically gathered and that allowed us to conduct such analysis, yielding relevant inferences about genotype distribution and HCV transmission dynamics.
In conclusion, geography appears to be the principal determinant of HCV genotype distribution. Genotype 1 is associated with transmission through high-risk clinical procedures, such as blood transfusions, hemodialysis, and medical injections; while genotype 3 is associated with transmission through injecting drug use. These findings demonstrate the power of such an analytical approach, which if extended to other regions and globally, may yield relevant epidemiological inferences that can inform control and treatment programs. 
